The estimated Net Worth of Eilon D. Kirson is at least $5.74 Million dollars as of 27 February 2019. Eilon Kirson owns over 6,945 units of NovoCure Ltd stock worth over $2,625,990 and over the last 9 years Eilon sold NVCR stock worth over $3,112,337.
Eilon has made over 18 trades of the NovoCure Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently Eilon exercised 6,945 units of NVCR stock worth $367,391 on 27 February 2019.
The largest trade Eilon's ever made was exercising 346,161 units of NovoCure Ltd stock on 4 June 2018 worth over $2,468,128. On average, Eilon trades about 50,921 units every 40 days since 2016. As of 27 February 2019 Eilon still owns at least 152,408 units of NovoCure Ltd stock.
You can see the complete history of Eilon Kirson stock trades at the bottom of the page.
Eilon's mailing address filed with the SEC is C/O NOVOCURE INC.,, 20 VALLEY STREAM PKWY SUITE 300, MALVERN, PA, 19355.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ..., and Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: